Article Date

BioPhorum’s latest Technology Strategy explores “How to develop a control strategy for continuous bioprocesses”.

Cost-effective, rapid, and flexible biopharmaceutical production is an industry-wide challenge. Process intensification through continuous manufacturing has proved successful in other industries and is a promising area of investigation for researchers, vendors, and biomanufacturers.

Said Charles Heffernan, Director of Advanced Therapies and Biologics with PM Group;

“Continuous bioprocessing is the next evolution in cost-effective manufacture for certain therapies. I’m very excited to have collaborated with the BioPhorum team to articulate a control framework that will reduce barriers to entry for biomanufacturers. We are actively working on projects that will leverage these methodologies and will be excited to see them in practice!”


The Technology Strategy examines the simplification of linkages between unit operations in collaboration with Asahi Kasei, CRB, Emerson, Exyte, FUJIFILM Diosynth Biotechnologies, GSK, Janssen Inc., Lonza, Cytiva, Rockwell Automation, Siemens, Thermo Fisher Scientific, Merck Group, Novo Nordisk, PM Group Sartorious Stedim and Schneider Electric


Facilitated by Graeme Moody


Read more about this here